Talapotaka churna in Diabetes Mellitus

Pharmaceutical, analytical, preclinical and clinical study of Talapotaka churna in the management of type-2 Diabetes mellitus - TPC in DM II

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2016/09/007259

Enrollment

Registered

2016-09-08

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Type II Diabetes mellitus

Interventions

Intervention1: Talapotak Churna: Talapotak Churna 4 gm TIDS for 2 Months Intervention2: NIL: NIL Intervention3: Talapotak Churna: Study of Talapotak Churna in the management of Type II Diabetes Melli

Eligibility

Inclusion criteria

Inclusion criteria: Blood Sugar Leval Fasting - >126 mg/dl - Postprandial - >200 mg/dl - <350 mg/dl

Exclusion criteria

Exclusion criteria: Diabetes mellitus Type I and Type II with serious complications like Nephropathy, CAD etc.

Design outcomes

Primary

Measure	Time frame
Normalized Blood Sugar Level and improved HbA1C in good no of cases.Timepoint: 2 Months	—

Secondary

Measure	Time frame
Normalized lipid profile in most of cases.Timepoint: 2Months	—

Countries

India

Contacts

Public ContactDr Guruprasad C Nille

Institute of Medical Sciences, BHU

drkrcreddybhu@yahoo.co.in9415813533

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026